DOCK9 Antibody

What is DOCK9 and what are its primary functions in cellular processes?

DOCK9 (dedicator of cytokinesis 9) is a guanine nucleotide exchange factor (GEF) that specifically activates CDC42 by exchanging bound GDP for free GTP. Its primary function involves cytoskeletal reorganization, with overexpression inducing filopodia formation . DOCK9 belongs to the DOCK-D or Zizimin subfamily along with DOCK10 and DOCK11 . This protein plays critical roles in multiple cellular processes including cell migration, morphogenesis, and adhesion by regulating Rho GTPase activity, which makes it an important target for research in neurodevelopment, cancer progression, and cardiovascular disorders.

What tissue and cell types show significant DOCK9 expression?

DOCK9 expression varies across tissues and cell types, with different isoforms showing distinct expression patterns. According to comprehensive expression studies, DOCK9 isoforms (DOCK9.1 and DOCK9.2) are widely distributed, with high expression levels detected in:

• Lungs, placenta, uterus, and thyroid gland (both isoforms)

• Neural tissues (predominantly DOCK9.1)

• Hematopoietic tissues (predominantly DOCK9.1)

• Various cell lines including A549, HeLa, and MCF-7 cells

• Human and mouse brain tissue

• Human heart tissue and human placenta tissue

This expression pattern suggests tissue-specific functions for different DOCK9 isoforms, which researchers should consider when designing experiments targeting specific biological contexts.

What are the key specifications of commercial DOCK9 antibodies?

Commercial DOCK9 antibodies, such as the 18987-1-AP, have the following specifications:

When selecting an antibody for your research, confirm that it has been validated for your specific application and species of interest.

What are the recommended dilutions and protocols for different DOCK9 antibody applications?

The recommended dilutions for DOCK9 antibody applications vary based on the experimental technique:

For optimal results, it's recommended to:

• Test various dilutions within the recommended range to determine optimal concentration for your specific sample type

• For IHC applications, perform antigen retrieval with TE buffer pH 9.0 or alternatively with citrate buffer pH 6.0

• Titrate the antibody in each testing system to optimize signal-to-noise ratio

• Include appropriate positive and negative controls to validate specificity

Remember that optimal conditions may vary depending on sample type and preparation method.

How can I detect and differentiate between DOCK9 isoforms?

Detecting and differentiating between DOCK9 isoforms (DOCK9.1 and DOCK9.2) requires careful experimental design:

For mRNA detection:

• Use isoform-specific primers targeting the mutually exclusive first exons

• Validated qRT-PCR assays include primers targeting exon junctions e1.1-e2 for DOCK9.1 and e1.2-e2 for DOCK9.2

• For total DOCK9 detection, use primers targeting common regions like e27-e28 or e33-e34

For protein detection:

• Western blot analysis using antibodies targeting either specific N-terminal sequences or common regions

• Distinguish between isoforms based on slight molecular weight differences or by comparing with recombinant protein standards

• Use cell lines with known differential expression as positive controls

Research has shown that expression of DOCK9.1 and DOCK9.2 can differ significantly between tissues and cell lines, suggesting differential regulation . This necessitates careful consideration when designing experiments targeting specific isoforms.

What controls should be included when using DOCK9 antibodies for validation?

Proper validation of DOCK9 antibodies requires several types of controls:

Positive controls:

• Known DOCK9-expressing tissues/cells: A549 cells, human brain tissue, mouse brain tissue, human heart tissue, human placenta tissue, HeLa cells, MCF-7 cells

• Recombinant DOCK9 protein or overexpression lysates

Negative controls:

• Tissues/cells with knockout or knockdown of DOCK9

• Secondary antibody-only controls to assess non-specific binding

• Blocking peptide controls to confirm specificity

Additional validation approaches:

• Compare results with multiple DOCK9 antibodies targeting different epitopes

• Cross-reference protein and mRNA expression data

• For immunostaining applications, include pre-absorption controls with the immunizing peptide

Comprehensive validation is critical since antibody performance can vary significantly between applications and sample types.

How can DOCK9 isoform expression patterns be used as potential biomarkers in disease?

The differential expression of DOCK9 isoforms presents opportunities for biomarker development:

Research has demonstrated that DOCK9.1 and DOCK9.2 show tissue-specific expression patterns, with DOCK9.1 being significantly expressed in neural and hematopoietic tissues, while both isoforms show high expression in lungs, placenta, uterus, and thyroid gland . This differential expression may have implications for disease-specific biomarker development.

For researchers investigating DOCK9 as a potential biomarker:

• Establish baseline expression profiles in normal tissues using both mRNA analysis (qRT-PCR with isoform-specific primers) and protein analysis (Western blot)

• Compare expression between normal and pathological samples to identify disease-associated shifts in isoform ratios

• Validate findings across multiple platforms (qRT-PCR, Western blot, immunohistochemistry) and in larger cohorts

• Consider the expression of DOCK9-AS2 (antisense RNA2), which has been implicated in atherosclerosis by promoting vascular smooth muscle cell proliferation and migration

The fact that DOCK9 isoforms show differential regulation between tissues and cell lines suggests they may be regulated by tissue-specific factors or disease states, making them promising candidates for biomarker development.

What are the challenges in distinguishing DOCK9 from other DOCK family members in experimental settings?

Distinguishing DOCK9 from other DOCK family members presents several technical challenges:

Sequence homology considerations:

• DOCK9 belongs to the DOCK-D subfamily along with DOCK10 and DOCK11, which share structural similarities

• These proteins have conserved functional domains, particularly in the catalytic DHR2 domain

Experimental approaches to ensure specificity:

• Verify antibody specificity by testing cross-reactivity with recombinant DOCK10 and DOCK11 proteins

• As demonstrated in research, Western blot analysis of cells transfected with expression vectors for different DOCK-D family members can validate antibody specificity

• Use isoform-specific primers that target unique regions for mRNA detection

• Complement antibody-based detection with genetic approaches (siRNA knockdown, CRISPR knockout) to confirm specificity

Data interpretation considerations:

• When strong signals are detected in tissues known to express multiple DOCK family members, additional validation may be required

• Consider the molecular weight differences between family members (DOCK9: 200-236 kDa) when interpreting Western blot results

• Factor in that different DOCK family members may compensate for each other functionally

How does the regulation of DOCK9 mutually exclusive first exon isoforms differ between tissues and cell lines?

Research has revealed complex regulation patterns for DOCK9 isoforms:

Tissue-specific patterns:

• In human tissues, DOCK9.1 and DOCK9.2 expression showed significant correlation (R=0.751, p=1×10⁻⁵)

• Both isoforms were highly expressed in lungs, placenta, uterus, and thyroid gland

• Only DOCK9.1 showed significant expression in neural and hematopoietic tissues

Cell line differences:

• In cell lines, DOCK9.1 and DOCK9.2 expression showed weaker correlation (R=0.319, p=0.137, not significant)

• Expression patterns differed significantly from those observed in tissues

• This suggests differential regulation mechanisms between tissues and cultured cells

Regulatory implications:

• The lack of correlation between isoforms in cell lines suggests they may be regulated by different transcriptional mechanisms in vitro

• These differences highlight the importance of validating findings in both cell lines and primary tissues

• Researchers should consider these differential expression patterns when selecting appropriate experimental models

This complex regulation is important to consider when designing experiments to study DOCK9 function in different biological contexts.

What are common pitfalls in DOCK9 antibody-based experiments and how can they be addressed?

Researchers frequently encounter challenges when working with DOCK9 antibodies:

Challenge: High molecular weight detection difficulties

• Solution: Use lower percentage SDS-PAGE gels (6-7%) for better resolution of high molecular weight proteins

• Optimize transfer conditions for large proteins (longer transfer times, lower voltage, addition of SDS to transfer buffer)

• Consider using gradient gels for improved separation

Challenge: Weak or absent signal in Western blot

• Solution: Verify sample preparation to ensure protein integrity (use fresh samples, appropriate lysis buffers with protease inhibitors)

• Increase antibody concentration or extend incubation time

• Enhance detection sensitivity with amplification systems (e.g., biotin-streptavidin)

• For brain tissue samples, which show high DOCK9 expression, optimize extraction protocols to account for high lipid content

Challenge: Non-specific binding

• Solution: Increase blocking time and concentration (5% BSA or milk)

• Optimize washing steps (increase duration and number of washes)

• Pre-absorb antibody with non-specific proteins

• Validate specificity with knockout/knockdown controls

Challenge: Inconsistent results between experiments

• Solution: Standardize sample preparation and experimental conditions

• Use internal loading controls consistently

• Include positive control samples with known DOCK9 expression (A549 cells, human brain tissue)

• Consider the differential expression of isoforms when interpreting variable results

How can researchers optimize DOCK9 detection in challenging samples?

Optimizing DOCK9 detection in difficult samples requires specific approaches:

For low-expression samples:

• Enrich DOCK9 using immunoprecipitation before Western blot analysis

• Use signal amplification systems for immunohistochemistry

• For mRNA detection, consider digital PCR for enhanced sensitivity compared to standard qRT-PCR

• Longer exposure times for Western blot, while ensuring low background

For specific tissue types:

• Brain tissue: Special consideration for antigen retrieval (TE buffer pH 9.0 recommended)

• Fixed tissues: Extended antigen retrieval times may be necessary

• For IHC applications in kidney and heart tissues, which have shown positive detection, optimal dilution ranges from 1:50-1:500

For subcellular localization studies:

• Optimize fixation conditions (different fixatives can affect epitope accessibility)

• Consider detergent concentration carefully during permeabilization

• For IF/ICC applications in cells like HeLa, use recommended dilutions of 1:200-1:800

• Complement antibody detection with subcellular fractionation studies

General optimization strategies:

• Test different buffer systems and pH conditions

• Optimize protein extraction protocols for specific sample types

• Consider native versus denaturing conditions depending on epitope configuration

• Validate findings with orthogonal detection methods

What is the role of DOCK9 in disease pathogenesis based on recent research?

Recent research has implicated DOCK9 in several disease processes:

Cardiovascular disease:

• DOCK9-AS2 (antisense RNA2) has been shown to promote vascular smooth muscle cell (VSMC) proliferation and migration in atherosclerosis models

• Knockdown of DOCK9-AS2 suppressed cell viability and migration in ox-LDL-induced VSMCs, suggesting its potential role in atherosclerosis progression

• DOCK9-AS2 appears to exert its effects through regulation of the Wnt5a pathway

Neurological functions:

• The high expression of DOCK9.1 in neural tissues suggests potential roles in nervous system development and function

• As a regulator of CDC42, DOCK9 likely influences neuronal morphogenesis and migration

Cancer progression:

• Given its role in cell migration and cytoskeletal reorganization, DOCK9 may contribute to cancer cell invasion and metastasis

• Differential expression in various cell lines suggests potential tissue-specific roles in cancer biology

Potential therapeutic implications:

• The specific regulation patterns of DOCK9 isoforms suggest they could be targeted selectively for tissue-specific interventions

• DOCK9-AS2 may represent a novel therapeutic target for atherosclerosis

• As a GEF for CDC42, inhibitors of DOCK9 activity could modulate cytoskeletal dynamics in pathological contexts

How does the function of DOCK9 differ from and interact with other DOCK family members?

Understanding the functional relationships between DOCK family members is crucial for comprehensive research:

Subfamilies and structural relationships:

• DOCK9 belongs to the DOCK-D (Zizimin) subfamily along with DOCK10 and DOCK11

• Other DOCK subfamilies include DOCK-A (DOCK1, DOCK2, DOCK5), DOCK-B (DOCK3, DOCK4), and DOCK-C (DOCK6, DOCK7, DOCK8)

Substrate specificity:

• DOCK9 specifically activates CDC42 through its GEF activity

• Other DOCK proteins activate different Rho GTPases (e.g., DOCK1-5 activate Rac, DOCK6-8 activate both Rac and CDC42)

Expression patterns and functional implications:

• While DOCK9 shows tissue-specific isoform expression, DOCK11 (also from DOCK-D subfamily) is highly expressed in hematopoietic tissues and others like lungs, placenta, uterus, and thyroid gland

• The differential expression suggests specialized functions in different cellular contexts

• Linear regression analysis between DOCK9 and DOCK11 expression shows distinct patterns in tissues versus cell lines

Research considerations:

• When investigating DOCK9 function, consider potential compensatory mechanisms from other DOCK family members

• Use highly specific antibodies validated against other DOCK proteins to avoid cross-reactivity

• Consider the collective role of DOCK proteins in coordinating cytoskeletal dynamics

• When targeting DOCK9 with inhibitors or genetic approaches, monitor potential effects on other family members

What emerging techniques might improve DOCK9 detection and functional analysis?

Several cutting-edge approaches hold promise for advancing DOCK9 research:

Advanced antibody technologies:

• Nanobodies and single-domain antibodies for improved specificity and subcellular access

• Proximity labeling techniques (BioID, APEX) to identify DOCK9 interaction partners in native contexts

• Bispecific antibodies for simultaneous detection of DOCK9 and its interacting proteins

Genetic engineering approaches:

• CRISPR-based endogenous tagging of DOCK9 for live-cell imaging without overexpression artifacts

• Isoform-specific knockouts to study differential functions

• Optogenetic control of DOCK9 activity to study temporal aspects of signaling

Advanced imaging methods:

• Super-resolution microscopy (STED, PALM, STORM) for nanoscale localization studies

• Förster resonance energy transfer (FRET) sensors to monitor DOCK9-CDC42 interactions in real-time

• Intravital imaging to study DOCK9 dynamics in physiological contexts

Biochemical and structural approaches:

• Hydrogen-deuterium exchange mass spectrometry to study conformational dynamics

• Cryo-EM structures of DOCK9 in complex with regulatory partners

• Activity-based protein profiling to assess catalytic activity rather than just expression

These emerging techniques could address current limitations in detecting, localizing, and functionally characterizing DOCK9 in complex biological systems.

How can researchers better investigate the interplay between DOCK9 and its signaling partners?

Investigating DOCK9 signaling networks requires specialized approaches:

Protein-protein interaction analysis:

• Proximity ligation assays to detect endogenous interactions between DOCK9 and CDC42 or other partners

• Co-immunoprecipitation followed by mass spectrometry to identify novel interacting proteins

• Yeast two-hybrid or mammalian two-hybrid screening to map interaction domains

Signaling pathway analysis:

• Phosphoproteomic analysis following DOCK9 activation or inhibition

• CRISPR screens to identify synthetic lethal interactions with DOCK9

• Multiplexed immunoassays to measure multiple pathway components simultaneously

Dynamic analysis approaches:

• Live-cell FRET sensors to monitor GEF activity in real-time

• Fluorescence recovery after photobleaching (FRAP) to assess DOCK9 mobility and interactions

• Single-molecule tracking to reveal nanoscale organization and dynamics

Computational approaches:

• Network analysis to predict and map DOCK9 signaling nodes

• Molecular dynamics simulations of DOCK9-CDC42 interactions

• Integration of multi-omics data to place DOCK9 in broader signaling contexts

By integrating these approaches, researchers can develop a more comprehensive understanding of how DOCK9 functions within complex cellular signaling networks and how its dysregulation contributes to disease processes.